EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer. He M, Gouda M, Gires O. Oral Oncol 2023;143:106465.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

He M, Gouda M, Gires O. EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer. Oral Oncol 2023;143:106465.
PMID: 37348447